Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001266707 | SCV001444884 | pathogenic | Inborn genetic diseases | 2017-11-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001386469 | SCV001586700 | pathogenic | not provided | 2024-01-09 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1450*) in the COL4A3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in COL4A3 are known to be pathogenic (PMID: 8956999, 24854265, 26809805, 27281700). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Alport syndrome (PMID: 33040356). ClinVar contains an entry for this variant (Variation ID: 985677). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002486013 | SCV002788100 | likely pathogenic | Autosomal dominant Alport syndrome; Autosomal recessive Alport syndrome; Benign familial hematuria | 2021-11-13 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001830069 | SCV002076431 | pathogenic | Alport syndrome | 2021-07-01 | no assertion criteria provided | clinical testing |